In 2010, Antibiotice posted net profit of RON12.5 million.
The company reported sales of RON281.8 million (EUR66.5 million) in 2011, from RON243.6 million a year earlier.
Overall revenue rose 15% on the year to RON302.5 million, while total costs increased 13% to RON276.1 million, according to the company’s preliminary results.
The pharmaceuticals company reported total debts of RON141.4 million at the end of December, up 28% on the year.
Antibiotice is the second-largest nystatin maker in the world, with a 25% market share, according to company information.
The company’s majority holder is Romania’s Health Ministry, with a 53% stake, while investment fund SIF Oltenia (SIF5.RO) holds a 10% stake.
On the Bucharest bourse Friday, Antibiotice closed up 0.32% at RON0.4125 a share. (EUR1=RON4.3477)